Xencor, Vir partner on COVID-19 antibodies research

By The Science Advisory Board staff writers

Biopharmaceutical companies Xencor and Vir Biotechnology have entered into a technology licensing agreement to develop potential antibody-based treatments for patients with COVID-19.

Under the agreement, Vir will receive nonexclusive access to Xencor's Xtend Fc technology that extends the half-life of antibodies. Vir will also be responsible for costs and activities pertaining to research, development, regulatory, and commercial actions.

The two companies previously partnered in 2019 on developing and commercializing antibodies for influenza and hepatitis B infections.

Copyright © 2020 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking